{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"115"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"26"}],"units":"Participants"}],"description":"The RP2D of abemaciclib was determined based on the totality of safety, tolerability, and pharmacokinetic results. RP2D of abemaciclib in combination with 150 mg/m²/day temozolomide on days 1-5 of 21-day cycles was reported.","groups":[{"description":"Participants received:\n\n* Abemaciclib: 70 mg/m² or 90 mg/m² or 115 mg/m², administered orally BID.\n* Temozolomide: 100 mg/m²/day or 150 mg/m²/day, administered orally on Days 1-5 of each cycle.\n\nTreatment continued until progressive disease, a discontinuation criterion, or unacceptable toxicity. Each cycle lasted 21 days.","id":"OG000","title":"Part B - Abemaciclib"}],"paramType":"NUMBER","populationDescription":"All participants in Part B who received at least one dose of abemaciclib and had evaluable data for this outcome.","reportingStatus":"POSTED","timeFrame":"Cycles 1 and 2 (21 Day Cycles)","title":"RP2D of Abemaciclib in Combination With Temozolomide (Part B)","type":"PRIMARY","unitOfMeasure":"mg/m² BID"}